Inotuzumab + Blinatumomab for Acute Lymphoblastic Leukemia

Not currently recruiting at 308 trial locations

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: National Cancer Institute (NCI)

Must not be taking: Antidepressants, Antipsychotics

Disqualifiers: CNS leukemia, Cardiac disease, Liver disease, Neurologic disorder, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Breakthrough Therapy This drug has been fast-tracked for approval by the FDA given its high promise

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests two treatments, inotuzumab ozogamicin and blinatumomab, to evaluate their effectiveness against CD22-positive B-lineage acute lymphoblastic leukemia (ALL). These drugs are a type of immunotherapy, designed to help the immune system fight cancer cells. Suitable candidates for this trial include individuals with newly diagnosed ALL, those whose ALL has returned after treatment, or those who haven't responded to other treatments. Participants should have a specific leukemia profile, such as being Philadelphia chromosome/BCR-ABL1-negative, and show no active signs of cancer in the central nervous system. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, certain prior treatments for leukemia must be completed at least 14 days before starting the trial, with some exceptions like intrathecal chemotherapy and corticosteroids, which must be completed 24 hours before starting the trial.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that the combination of inotuzumab ozogamicin and blinatumomab has been studied for safety in people with acute lymphoblastic leukemia. These studies indicate that this treatment is generally well-tolerated. Some patients have experienced common side effects, such as low blood cell counts, which can increase the risk of infections, and changes in liver function.

Inotuzumab ozogamicin has been used in other leukemia treatments, and its safety is well-known. Blinatumomab is also approved for treating certain types of leukemia and has a recognized safety record. Together, these drugs aim to help the immune system fight cancer, and their combination has been tested in trials to ensure safety.

While side effects can occur, this combination has shown promise in managing leukemia symptoms. Patients interested in joining a trial should talk to their healthcare provider to fully understand the potential risks and benefits. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about using inotuzumab ozogamicin and blinatumomab for treating acute lymphoblastic leukemia (ALL) because they offer a novel approach compared to traditional chemotherapy. Inotuzumab ozogamicin is an antibody-drug conjugate that specifically targets CD22-positive cancer cells, delivering a potent toxin directly to the leukemia cells, which could minimize damage to healthy cells. Blinatumomab is a bispecific T-cell engager that connects T-cells to cancer cells, helping the immune system to attack the leukemia more effectively. This combination could lead to more targeted and potentially more effective treatment, with fewer side effects than the standard chemotherapy options.

What evidence suggests that inotuzumab ozogamicin and blinatumomab might be effective treatments for acute lymphoblastic leukemia?

Research has shown that two treatments, inotuzumab ozogamicin and blinatumomab, hold promise for treating acute lymphoblastic leukemia (ALL). This trial will administer a combination of both inotuzumab ozogamicin and blinatumomab to participants. Inotuzumab ozogamicin proves effective as an initial treatment, while blinatumomab achieves similar success in patients whose ALL has returned or not responded to other treatments. These treatments, known as monoclonal antibodies, help the immune system identify and attack leukemia cells. Studies suggest these drugs can yield better results than standard treatments. Overall, evidence supports their use in managing CD22-positive B-lineage ALL. ^{4 6 7 8 9}

Who Is on the Research Team?

Matthew J Wieduwilt

Principal Investigator

Alliance for Clinical Trials in Oncology

Are You a Good Fit for This Trial?

This trial is for patients with CD22-positive B-lineage acute lymphoblastic leukemia (ALL) that's new, returned, or resistant to treatment. Eligible participants must not have active central nervous system (CNS) leukemia and should be negative for the Philadelphia chromosome/BCR-ABL1. They need a bone marrow sample sent to HEME Biobank before joining.

Inclusion Criteria

The cerebrospinal fluid (CSF) shows abnormal levels of white blood cells (WBC) or red blood cells (RBC) with abnormal findings in a special test called cytospin for cancer cells.

I received a specific spinal injection before joining the trial and started chemotherapy within 7 days after that.

I have been diagnosed with precursor B-cell acute lymphoblastic leukemia, not Burkitt lymphoma.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Induction Treatment

Patients receive inotuzumab ozogamicin intravenously over 1 hour on days 1, 8, and 15. Treatment continues for 1 course (28 days) in the absence of disease progression or unacceptable toxicity.

4 weeks

Consolidation Treatment

Patients receive blinatumomab IV continuously on days 1-28 and 43-70. Treatment continues for 1 course (84 days) in the absence of disease progression or unacceptable toxicity.

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 10 years

What Are the Treatments Tested in This Trial?

Interventions

• Blinatumomab
• Inotuzumab Ozogamicin

Trial Overview

The study tests how well two monoclonal antibodies, inotuzumab ozogamicin and blinatumomab, treat ALL by helping the immune system attack cancer cells and preventing their growth. It's a phase II trial focusing on those who haven't responded well to previous treatments or are newly diagnosed.

How Is the Trial Designed?

Group I: Cohort 2 (inotuzumab ozogamicin, blinatumomab) Experimental Treatment 2 Interventions

See Detailed Description.

Group II: Cohort 1 (inotuzumab ozogamicin, blinatumomab) Experimental Treatment 2 Interventions

See Detailed Description

Blinatumomab is already approved in European Union, United States for the following indications:

Approved in European Union as Blincyto for:

• Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
• High-risk first relapse BCP-ALL

Approved in United States as Blincyto for:

• Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
• First or second complete remission with minimal residual disease (MRD)

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials

14,080

Recruited

41,180,000+

Published Research Related to This Trial

Blinatumomab is estimated to be cost-effective compared to inotuzumab for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, with cost-effectiveness ranging from $4006 to $20,737 per quality-adjusted life-year (QALY) gained.

The analysis was based on a comprehensive model using data from the TOWER and INO-VATE-ALL trials, which included health outcomes like complete remission rates and overall survival, adjusted to match patient populations, indicating a thorough evaluation of both efficacy and economic impact.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States. Delea, TE., Zhang, X., Amdahl, J., et al.[2023]

Blinatumomab shows a favorable safety profile in pediatric patients with B-cell acute lymphoblastic leukemia (ALL), associated with a lower risk of serious adverse events, febrile neutropenia, and infections compared to traditional chemotherapy.

While blinatumomab does not significantly increase the risk of cytokine release syndrome or seizures, it is linked to a higher risk of encephalopathy, indicating the need for careful monitoring during treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis. Marrapodi, MM., Mascolo, A., di Mauro, G., et al.[2022]

Blinatumomab showed a median overall survival (OS) of 9.3 months compared to 7.7 months for inotuzumab ozogamicin (InO), suggesting a potential survival benefit for blinatumomab in adult patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) after adjusting for patient characteristics.

The complete remission (CR) rates were similar between blinatumomab and InO, indicating that while blinatumomab may offer better overall survival, both treatments are comparable in terms of achieving remission.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia. Song, J., Ma, Q., Gao, W., et al.[2021]

In a study of 34 adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), blinatumomab achieved a complete remission (CR) rate of 69%, with 78% of those patients reaching minimal residual disease (MRD) negativity, indicating effective treatment outcomes.

Inotuzumab ozogamicin showed an even higher CR rate of 94% in patients with overt r/r B-ALL, with 67% achieving MRD negativity, suggesting both treatments are highly effective salvage options for this aggressive leukemia.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis. Stelmach, P., Wethmar, K., Groth, C., et al.[2021]

In a study of 29 children with acute lymphoblastic leukaemia (ALL) treated with blinatumomab and/or inotuzumab, the complete remission rate was 47.6%, indicating these therapies can be effective alternatives to traditional chemotherapy, especially in heavily pretreated patients.

Both treatments showed promise in reducing minimal residual disease and delaying further chemotherapy, with manageable safety profiles, as only six patients experienced grade 3 reversible non-haematological toxicity.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP). Fuster, JL., Molinos-Quintana, A., Fuentes, C., et al.[2021]

In a study of 71 patients with relapsed/refractory B-lymphoblastic leukemia, treatment with blinatumomab (Blina) and inotuzumab ozogamicin (InO) resulted in high rates of complete remission (CR), with 63% achieving CR after Blina and 82% after InO, indicating strong efficacy for these immunotherapies.

The median overall survival for patients treated with Blina/InO was 19 months, and the disease-free survival was significantly better for patients with negative minimal residual disease (MRD-) compared to those with positive MRD, highlighting the importance of MRD status in treatment outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study. Fracchiolla, NS., Sciumè, M., Papayannidis, C., et al.[2023]

Inotuzumab ozogamicin (InO) demonstrated significantly higher rates of remission and hematopoietic stem cell transplantation (HSCT) compared to blinatumomab (Blina) in adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL), based on indirect treatment comparisons involving patient-level data from 746 participants.

While both treatments showed similar overall survival rates, the analyses indicated a trend favoring InO for event-free survival, suggesting it may offer better outcomes in terms of remission and subsequent treatment options.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia. Proskorovsky, I., Su, Y., Fahrbach, K., et al.[2020]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC6824351/

Matching-Adjusted Indirect Comparison of Blinatumomab vs ...

Blinatumomab demonstrated a similar CR rate and potential OS benefit versus InO among adult patients with R/R ALL who received no more than one prior salvage ...

2.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/31218655/

Cost Effectiveness of Blinatumomab Versus Inotuzumab ...

Blinatumomab is estimated to be cost effective versus inotuzumab in R/R B-cell precursor ALL adults who have received one or no prior salvage therapy from a US ...

3.

clinicaltrials.gov

clinicaltrials.gov/study/NCT03739814

Study Details | NCT03739814 | Inotuzumab Ozogamicin ...

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia.

4.

sciencedirect.com

sciencedirect.com/science/article/pii/S2152265024024662

Inotuzumab Ozogamicin as First-Line Therapy in Acute ...

This review summarizes the efficacy and safety results of several recent trials investigating different approaches with InO as first-line therapy in patients ...

5.

asco.org

asco.org/abstracts-presentations/ABSTRACT228527

Indirect treatment comparison of blinatumomab versus ...

Background: Blinatumomab (BLIN) and inotuzumab ozogamicin (INO) have demonstrated improved outcomes against standard of care (SOC) among adult patients with ...

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12533514/

Inotuzumab ozogamicin in adult acute lymphoblastic leukemia

Outcomes have been historically poor in adults with relapsed/refractory (R/R) B-cell ALL, with a 5-year overall survival (OS) rate of <10% with ...

7.

clinicaltrials.gov

clinicaltrials.gov/study/NCT03739814

Study Details | NCT03739814 | Inotuzumab Ozogamicin ...

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia.

8.

ascopubs.org

ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.6541

Outcomes in patients with B-cell precursor acute ...

In this pooled analysis of pts treated with InO for R/R B-ALL, efficacy and safety outcomes were broadly consistent across BMI groups.

9.

aetna.com

aetna.com/cpb/medical/data/900_999/0919.html?ref=counterforcehealth.org

Inotuzumab Ozogamicin (Besponsa) - Medical Clinical ...

Jabbour et al (2023) noted that the outcome of older patients with B-cell acute lymphocytic leukemia is inferior to that in younger patients due to the adverse ...